FDA Authorizes First Oral Antiviral for Treatment of COVID-19
Last Updated: Dec 22, 2021
On Wednesday, the FDA issued an emergency use authorization for Pfizer’s Paxlovid, an antiviral pill for oral use, to treat mild-to-moderate COVID-19 in adults and children ages 12 years of age and older. Patients with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death can receive the prescription. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.